Nausea and vomiting during high-dose interleukin-2 (HD IL-2) therapy.

被引：0
|
作者：
Fesler, Mark
Chu, Melinda Bernabe
Armbrecht, Eric
Fosko, Scott
Hsueh, Eddy C.
Richart, John M.
机构：
[1] St Louis Univ, St Louis, MO 63103 USA
[2] St Louis Univ, Ctr Outcomes Res, St Louis, MO 63103 USA
[3] St Louis Univ, Dept Dermatol, St Louis, MO 63103 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20661
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Maintenance interleukin-2 (IL-2) and sargramostim (GM-CSF) following high-dose IL-2 (HD IL-2) therapy for metastatic melanoma
    Chu, Melinda Bernabe
    Fesler, Mark
    Armbrecht, Eric
    Fosko, Scott
    Hsueh, Eddy C.
    Richart, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma
    Powell, S. F.
    Dudek, A. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] High-dose interleukin-2 (HD IL-2) in the treatment of advanced melanoma: The University of Pittsburgh experience
    Davar, Diwakar
    Saul, Melissa
    Tarhini, Ahmad A.
    An Tran
    Trent, Kerry
    Sander, Cindy
    Kirkwood, John M.
    Tawbi, Hussein Abdul-Hassan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
    Buchbinder, Elizabeth I.
    Gunturi, Anasuya
    Perritt, Jessica
    Dutcher, Janice
    Aung, Sandra
    Kaufman, Howard L.
    Ernstoff, Marc S.
    Miletello, Girald P.
    Curti, Brendan D.
    Daniels, Gregory A.
    Patel, Sapna P.
    Kirkwood, John M.
    Hallmeyer, Sigrun
    Clark, Joseph I.
    Gonzalez, Rene
    Richart, John M.
    Lutzky, Joe
    Morse, Michael A.
    Sullivan, Ryan J.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [5] Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
    Clark, Joseph
    Morse, Michael A.
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Perritt, Jessica C.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] PLASMA-FREE CATECHOLAMINES IN PATIENTS DURING IMMUNOTHERAPY WITH HIGH-DOSE INTERLEUKIN-2 (IL-2)
    MARCUS, SL
    DUTCHER, JP
    PAIETTA, E
    CIOBANU, N
    WIERNIK, PH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 369 - 369
  • [7] A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma
    Wargo, Jennifer Ann
    Lawrence, Donald P.
    Cooper, Zachary A.
    Frederick, Dennie T.
    Giobbie-Hurder, Anita
    Piris, Adriano
    Rubin, Krista M.
    Fadden, Riley
    Reuben, Alexandre
    Starker, Lee
    Flaherty, Keith
    Sharpe, Arlene
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Single-institution Outcome of High-dose Interleukin-2 (HD IL-2) Therapy for Metastatic Melanoma and Analysis of Favorable Response in Brain Metastases
    Powell, Steven
    Dudek, Arkadiusz Z.
    ANTICANCER RESEARCH, 2009, 29 (10) : 4189 - 4193
  • [9] High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions
    Marabondo, Stephen
    Kaufman, Howard L.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) : 1347 - 1357
  • [10] A PHASE-I-II TRIAL OF OUTPATIENT HIGH-DOSE INTERLEUKIN-2 (IL-2)
    RICHARDS, JM
    RAMMING, K
    BARKER, E
    VOGELZANG, NJ
    CLINICAL RESEARCH, 1987, 35 (06): : A864 - A864
12345